Skip to main content
. 2017 Apr 5;8(20):33796–33806. doi: 10.18632/oncotarget.16840

Figure 4. The established prognostic model was validated in 104 patients with advanced KRAS+/TP53+ mutant cancer who did not receive therapy in a phase I clinical trial.

Figure 4

Kaplan-Meier overall survival (OS) curves are shown, stratified by risk score (low-risk group: score ≤1, high-risk group: score >1) (due to sample size, all p values are unadjusted).